ArticleJournal of virology2026
Porcine reproductive and respiratory syndrome virus antagonizes the host restriction factor SHFL to sustain viral programmed ribosomal frameshifting and replication.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The global pandemic of porcine reproductive and respiratory syndrome virus (PRRSV) and its continuous evolution pose a sustained threat to the swine industry, underscoring the urgent need for a broad-spectrum antiviral strategy. Programmed ribosomal frameshifting (PRF) is an essential mechanism in PRRSV that directs the synthesis of viral nonstructural proteins (nsps) and represents an attractive antiviral target. Here, we show that SHFL, an interferon-stimulated gene (ISG), restricts PRRSV infection by specifically targeting viral biosynthesis steps. Mechanistically, SHFL inhibits the canonical programmed -1 ribosomal frameshifting (-1 PRF) of PRRSV, thereby suppressing RNA replication. SHFL also effectively blocks PRRSV -2 PRF, demonstrating its broad-spectrum activity against different frameshifting mechanisms. To sustain viral replication, PRRSV employs its nsp12 and nucleocapsid (N) proteins to counteract the expression of SHFL transcriptionally, thereby attenuating this host antiviral defense. These findings identify SHFL as a broad-spectrum PRF inhibitor against PRRSV, further elucidating its antiviral mechanisms of SHFL. The discovery that PRRSV proteins antagonize SHFL not only deepens our understanding of PRRSV pathogenesis but also highlights the dynamic interplay between virus and host.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.